It didn't take a high-powered academic to figure out why Scholar Rock 's (NASDAQ: SRRK) share price swooned by more than 5% ...

Q2 2025 Management View CEO David L. Hallal emphasized Scholar Rock is “scaling for the next phase of growth as a commercial stage fully integrated global biopharmaceutical company.” He outlined three ...

August 6, 2025Scholar Rock Holding Corporation misses on earnings expectations. Reported EPS is $-0.98 EPS, expectations were $-0.66. Operator: Good morning, ladies and gentlemen, and welcome to the ...

No revenue was recorded as the company remains pre-commercial, in line with analyst expectations. R&D and G&A expenses surged 47% and 191% year over year as apitegromab advanced toward anticipated U.S ...

Detailed price information for Scholar Rock Holding Corp (SRRK-Q) from The Globe and Mail including charting and trades.

Shares of Scholar Rock (NASDAQ: SRRK) shot 364% higher on Monday, Oct. 7, 2024. The market was reacting to surprisingly positive news regarding the clinical-stage drugmaker's lead candidate ...

“Scholar Rock has entered 2025 from a position of financial strength, and the successful public offering completed in October 2024 will support both the planned commercial launch of apitegromab ...

Scholar Rock's cash burn was increasing - net losses between 2020 and 2023 were $ (86.5m), $ (132m), $ (135m), and $ (166m), and its share price had declined to ~$6.5 by October 2023.

Scholar Rock's stock is down 45% in the year through Friday's close, while the S&P 500 SPX has gained 20.6%. -Ciara Linnane ...

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases ...

Shares of Scholar Rock Holding (NASDAQ: SRRK) are soaring today, up 13.7% as of 1:14 p.m. ET. The move comes as the S&P 500 and Nasdaq Composite were up modestly.

The biotech company Scholar Rock reported Monday that its experimental medicine improved motor function in patients with a muscle-wasting disease called spinal muscular atrophy, paving the way for ...